About Theravance Biopharma, Inc.
https://www.theravance.comTheravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD).
CEO
Rick E. Winningham
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 106
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
WOODFORD INVESTMENT MANAGEMENT LTD
Shares:11.35M
Value:$233.94M
MADISON AVENUE PARTNERS, LP
Shares:9.51M
Value:$196.02M
WEISS ASSET MANAGEMENT LP
Shares:7.46M
Value:$153.69M
Summary
Showing Top 3 of 206
About Theravance Biopharma, Inc.
https://www.theravance.comTheravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $19.99M ▼ | $18.33M ▼ | $3.62M ▼ | 18.08% ▼ | $0.07 ▼ | $-1.91M ▲ |
| Q2-2025 | $26.2M ▲ | $18.43M ▲ | $54.84M ▲ | 209.33% ▲ | $1.09 ▲ | $-2.32M ▲ |
| Q1-2025 | $15.39M ▼ | $18.37M ▼ | $-13.58M ▲ | -88.24% ▼ | $-0.27 ▲ | $-14.02M ▼ |
| Q4-2024 | $18.75M ▲ | $27.95M ▲ | $-15.53M ▼ | -82.79% ▼ | $-0.31 ▼ | $-7.6M ▲ |
| Q3-2024 | $16.87M | $18.44M | $-12.7M | -75.28% | $-0.26 | $-8.85M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $329.68M ▼ | $415.46M ▼ | $182.78M ▼ | $232.68M ▲ |
| Q2-2025 | $338.8M ▲ | $426.04M ▲ | $201.19M ▲ | $224.85M ▲ |
| Q1-2025 | $130.85M ▲ | $343.58M ▼ | $177.6M ▼ | $165.98M ▼ |
| Q4-2024 | $88.35M ▼ | $354.16M ▼ | $178.62M ▲ | $175.54M ▼ |
| Q3-2024 | $91.36M | $356.11M | $170.45M | $185.65M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.62M ▼ | $-6.51M ▼ | $-100.25M ▼ | $-400K ▲ | $-107.15M ▼ | $-6.51M ▼ |
| Q2-2025 | $54.84M ▲ | $208.07M ▲ | $-36.26M ▼ | $-503K ▲ | $171.31M ▲ | $208.04M ▲ |
| Q1-2025 | $-13.58M ▲ | $43.04M ▲ | $30.63M ▲ | $-854K ▼ | $72.82M ▲ | $43.04M ▲ |
| Q4-2024 | $-15.53M ▼ | $-902K ▲ | $15.69M ▲ | $-365K ▲ | $14.42M ▲ | $-1.09M ▲ |
| Q3-2024 | $-12.7M | $-5.2M | $-17.4M | $-372K | $-22.97M | $-5.21M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Collaboration revenue | $0 ▲ | $0 ▲ | $0 ▲ | $20.00M ▲ |
 Collaborative Arrangement Revenue | $0 ▲ | $20.00M ▲ | $20.00M ▲ | $0 ▼ |
 License | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $0 ▼ |
 YUPELRI Monotherapy | $20.00M ▲ | $0 ▼ | $20.00M ▲ | $20.00M ▲ |
CEO
Rick E. Winningham
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 106
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
WOODFORD INVESTMENT MANAGEMENT LTD
Shares:11.35M
Value:$233.94M
MADISON AVENUE PARTNERS, LP
Shares:9.51M
Value:$196.02M
WEISS ASSET MANAGEMENT LP
Shares:7.46M
Value:$153.69M
Summary
Showing Top 3 of 206